{"groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"FG000","title":"Phase I 5mg Ruxolitinib"},{"description":"Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"FG001","title":"Phase II"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"FG002","title":"Phase I 10 mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"FG003","title":"Phase I 15 mg Ruxolitinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Participant currently on study and in follow up status."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"comment":"The Phase II component of this trial did not start.","groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"comment":"The Phase II component of this trial did not start.","groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The 10 participants who completed the Phase I component of the trial did not continue to the Phase II component of the trial. This is because the Phase II component of the trial did not open."}